Schizophrenia afflicts approximately 3.6 million people in the world's seven major pharmaceutical markets (United States, France, Germany, Italy, Spain, United Kingdom, and Japan). Decision Resources, Inc., announces the publication of Schizophrenia, a new study that assesses the most promising new therapeutics in development to treat this chronic psychotic disorder.
The schizophrenia market will continue to be dominated by atypical antipsychotics as the availability and use of these agents in the seven markets increase over our 1999-2009 study period. The launch of Pfizer's atypical agent ziprasidone (Zeldox) in 2001 will mark the arrival of the first atypical antipsychotic that appears to cause little or no weight gain. Despite concerns related to the drug's cardiac side effect, ziprasidone received U.S. FDA Advisory Committee recommendation for approval in July 2000 because expert psychiatrists on the panel believed the need for an atypical agent that is weight-neutral outweighed the cardiac risk. Ziprasidone's freedom from weight effects and Pfizer's marketing muscle will combine to make the drug a formidable competitor in the schizophrenia market. Olanzapine and risperidone, however, will remain the schizophrenia market leaders throughout the forecast period because they will be available in new formulations.
Sales of antipsychotic drugs-for the treatment of schizophrenia alone- reached $2.3 billion in 1999 in the seven major markets. This figure amounts to more than half of total sales of these agents. (Sales of antipsychotic drugs for all disorders likely exceeded $3.8 billion in the seven major markets in 1999.) We expect sales for schizophrenia alone to grow to more than $3 billion by 2009, primarily as the result of broader availability and use of the more expensive atypical agents. Indeed, atypical antipsychotics will continue to dominate the schizophrenia market. By 2004, sales of atypicals will represent nearly 90% of the total antipsychotics market, a position that these agents will sustain through 2009. The arrival of new serotonin-dopamine antagonists and short- and long-acting injectable (depot) formulations of current agents will be the primary reasons for growth.
Schizophrenia is part of Cognos, one of six Pharmacor services that evaluate the commercial potential of drugs in research and development.
Decision Resources, Inc., is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Founded as a subsidiary of Arthur D. Little, Inc., the company has provided strategic information services for 30 years, assessing industry trends in the international health care and pharmaceutical industries.
Contact: Frank Sama, 781.296.2553 (telephone), 781.296.2550 (fax), or firstname.lastname@example.org (e-mail). In Europe, contact Francoise Bidart, +32.2.351.4082 (telephone), +32.2.351.2347 (fax), or email@example.com (e-mail). In Japan, contact Makiko Yoshimoto, +81.3.5401.2615 (telephone), +81.3.5401.2617 (fax), or firstname.lastname@example.org (e-mail). http://www.dresources.com
AP Archive: http://photoarchive.ap.org/
PRN Photo Desk, 888-776-6555 or 201-369-3467
SOURCE: Decision Resources, Inc.
Contact: Frank Sama of Decision Resources, Inc., 781-296-2553,